Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pulmonary embolism

Pulmonary embolism is the obstruction of one or more pulmonary arteries by material that has reached them through the circulation. In by far the most common form, this material is a fragment of a thrombus originating in the deep venous system and transported through the right atrium and ventricle. The term pulmonary thromboembolism specifically identifies this thrombotic nature and places the disease within the same biological process as deep vein thrombosis. The obstruction therefore affects arteries but usually originates from a disease of the veins; the absence of pain or swelling in a limb does not exclude this origin.

The best-known presentation is acute pulmonary embolism, in which the interruption of blood flow and the vascular response rapidly alter right ventricular workload and respiratory gas exchange. The clinical spectrum is broad: some episodes are discovered incidentally during examinations performed for other reasons, others cause pleuritic pain or dyspnea, and still others lead to circulatory failure and cardiac arrest. The anatomical location of the clot helps describe the disease but is not sufficient to predict its outcome. Right ventricular function, pre-existing cardiopulmonary reserve, the systemic response and any persistence of factors favoring further emboli are decisive.

The epidemiological impact must be interpreted by distinguishing recognized cases from undiagnosed sudden deaths and small emboli identified because of greater imaging sensitivity. Frequency increases with age, hospitalization, surgery, malignancy and immobility, but no adult age group is completely exempt. Improvements in diagnosis and treatment have changed prognosis without eliminating mortality from unstable presentations or the functional consequences experienced by survivors. The disease also has a late dimension: in a minority of individuals, the material is not completely resolved and becomes organized within the vascular wall, contributing to chronic obstruction with or without pulmonary hypertension.

Origin of emboli, pathogenesis and cardiopulmonary consequences

The usual source is deep vein thrombosis of the lower extremities or pelvis. Proximal thromboses are particularly important as potential sources of emboli because they involve larger vessels and may contain material capable of reaching the pulmonary circulation in substantial quantities. Veins of the upper extremities and central veins may also be involved, especially in the presence of catheters, intravascular devices, malignancies or anatomical compressions. Identifying the site of origin clarifies the clinical context but is not always possible: the thrombus may already have migrated, may be located in an unexamined region or may no longer be detectable at the time of investigation.
The connection with venous thromboembolic disease explains why treatment must protect the entire circulation against the formation of new thrombi rather than being limited to the clot already present in the lungs.

Predisposition results from the interaction between individual conditions and temporary circumstances. Stasis reduces the dilution of procoagulant factors; endothelial activation promotes cellular adhesion; hypercoagulability facilitates thrombin generation and fibrin deposition. Surgery often combines all these mechanisms through tissue injury, inflammation and reduced mobility. In cancer, coagulation activation by the malignancy may coexist with anticancer treatments, venous compression and central venous devices. Pregnancy, the postpartum period and estrogen treatments alter hemostatic balance, while inherited thrombophilias and antiphospholipid antibody syndrome represent additional predisposing conditions whose relevance varies among patients.

Clinically, it is useful to distinguish transient factors from persistent factors, also assessing their magnitude. Recent major surgery does not carry the same weight as prolonged travel; active malignancy is not equivalent to a remote, cured cancer. Some events occur without an identifiable precipitating factor: this does not demonstrate the absence of a biological predisposition and does not automatically require indiscriminate investigation for every possible coagulation abnormality. Reviewing exposures primarily serves to understand future risk and determine whether anticoagulant protection can be discontinued after the initial phase or should be continued.

Once an embolus reaches the lungs, it removes part of the vascular bed from the passage of blood. Mechanical obstruction is accompanied by vasoconstriction associated with vasoactive mediators and hypoxia. Increased resistance imposes a load on the right ventricle that may rise much more rapidly than its capacity to adapt. Dilation initially supports stroke volume by recruiting contractile reserve, but it increases wall tension and oxygen demand. When coronary perfusion becomes insufficient, contractility deteriorates and the circulation may enter a progressive spiral of failure.
The phenomenon also affects the left side of the heart: reduced pulmonary blood flow decreases return to the left atrium, while the septum displaced by the dilated right ventricle restricts ventricular filling. Systemic pressure may therefore fall even though the left ventricle was initially normal.

Respiratory consequences do not depend solely on the amount of lung parenchyma downstream of the occlusion. Ventilated but poorly perfused regions increase dead space; blood is redistributed toward other areas, where unfavorable ventilation/perfusion relationships may develop. Atelectasis and local surfactant abnormalities contribute further to these disturbances. In low-output states, venous blood reaches the lungs with lower oxygen saturation, amplifying hypoxemia. If right atrial pressure promotes right-to-left passage through an interatrial communication, an additional shunt may develop, reducing the response to oxygen therapy.
Hyperventilation explains the frequent reduction in carbon dioxide, but neither normal arterial blood gas results nor preserved oxygen saturation exclude clinically significant pulmonary embolism.

The lungs receive blood from both the pulmonary arteries and the bronchial circulation; this dual blood supply helps limit necrosis following occlusion. Pulmonary infarction may nevertheless develop, especially in peripheral regions, and often has a hemorrhagic component. Pleural irritation and alveolar involvement account for pain worsened by inspiration, mild hemoptysis and peripheral opacities. Pain intensity does not necessarily correspond to the risk of death: a small peripheral embolus may be very painful, whereas a hemodynamically significant obstruction may present primarily with dyspnea, presyncope or collapse.

Embolic material is not always a venous thrombus. Septic, fat, gas, tumor or other types of emboli belong to different clinical conditions in which the etiological context radically changes investigation and treatment. In situ pulmonary thrombosis, which may occur with vascular injury or intense inflammation, must also be distinguished from migration of a peripheral clot. An image showing a filling defect therefore does not fully establish the etiological diagnosis: morphology, distribution, clinical history and changes over time help identify situations that do not follow the course of ordinary thromboembolism.

Clinical manifestations and recognition of severity

The medical history first establishes the onset and progression of dyspnea. Onset may be sudden, but some patients report a progressive reduction in walking capacity or fluctuating episodes over the preceding days. Chest pain may be pleuritic when the peripheral lung is involved or more pressure-like when cardiac overload predominates. Cough, hemoptysis and low-grade fever are possible but do not constitute an obligatory combination. Syncope requires attention because it may reflect a transient fall in cardiac output; its significance must be assessed alongside blood pressure, oxygenation, right ventricular function and possible alternative explanations.

Personal history includes previous thrombotic episodes, surgical procedures, trauma, immobilization, hospital admissions, malignancies, pregnancy and hormone use. Any anticoagulant therapy already being taken must also be documented, including dosage, adherence and potential interactions: treatment reduces risk but does not eliminate it. Limb symptoms may precede respiratory symptoms, occur simultaneously or be entirely absent. In patients with chronic cardiac or pulmonary disease, comparing current symptoms with their usual functional status is particularly useful because a new embolism may present as an apparently nonspecific worsening of an established disease.

Physical examination begins with assessment of vital functions. Tachypnea, tachycardia, reduced oxygen saturation and increased work of breathing may raise suspicion but are not specific findings. Lung auscultation may be largely unremarkable even in the presence of marked dyspnea. Hypotension, cold extremities, altered mental status, oliguria and signs of venous congestion instead suggest hemodynamic compromise. Examination of the limbs may reveal asymmetric edema or tenderness that warrants venous investigation; traditional physical examination maneuvers alone neither confirm nor exclude thrombosis.

Severity is defined by the consequences of the embolism rather than isolated anatomical descriptions such as “bilateral” or “saddle”. In high-risk pulmonary embolism, circulatory instability requires immediate assessment and treatment. A normotensive patient may have preserved cardiac reserve or may instead show myocardial injury and right ventricular dysfunction. The latter situation belongs to the spectrum of intermediate-risk pulmonary embolism, in which the central issue is identifying patients who may deteriorate and establishing an appropriate level of monitoring.

European categories remain useful for distinguishing high, intermediate and low risk. The 2026 multidisciplinary AHA/ACC guidelines also propose clinical A–E categories describing progression from asymptomatic presentations to forms with cardiopulmonary failure. The two systems must not be superimposed using automatic equivalences. Preserved blood pressure alone does not guarantee safety, while an incidental finding does not necessarily imply hospitalization: what matters is integrating symptoms, vital signs, organ reserve and the patient’s overall condition. In low-risk pulmonary embolism, appropriate patient selection may allow home treatment or early discharge.

Investigations and diagnostic pathway

Diagnosis follows a reasoned sequence. In stable patients, clinical pretest probability is assessed first through medical evaluation and validated tools such as the Wells or Geneva scores. This estimate changes the significance of subsequent findings: a negative test is more reassuring when initial suspicion is low, whereas discordance between strong suspicion and an apparently normal result may require further investigation. Diagnostic scores do not measure the severity of an already confirmed pulmonary embolism and must not be confused with the prognostic tools used to decide on monitoring or discharge.

D-dimer reflects the degradation of cross-linked fibrin and is used primarily to exclude the disease within appropriate diagnostic pathways. An elevated result does not establish pulmonary embolism because it may accompany advanced age, inflammation, surgery, malignancy and pregnancy. In patients whose clinical probability is not high, a result below the threshold specified by the assay and algorithm may avoid imaging. Age-adjusted or clinical probability-adjusted threshold strategies improve diagnostic efficiency but must be applied in their validated form, respecting measurement units and the reference population.
When probability is high, ordering D-dimer in an attempt to exclude pulmonary embolism may delay the necessary investigation. In unstable patients, the pathway must likewise not be slowed by waiting for a marker designed primarily as an exclusion tool.

CT pulmonary angiography visualizes filling defects in the arteries and provides information about embolus distribution, right ventricular dimensions and alternative thoracic diagnoses. Technical quality is essential: motion, inadequate contrast opacification and small peripheral artifacts may make the result uncertain. A very distal filling defect must therefore be interpreted with particular care when it is inconsistent with the clinical presentation. The examination may also identify signs of pre-existing disease, such as intraluminal webs, irregular stenoses and organization of material along the vessel wall.

Ventilation/perfusion scintigraphy compares the distribution of air and blood in the lungs. A perfusion defect in a ventilated region may support the diagnosis, whereas a normal study has strong exclusion value. The choice between this examination and CT pulmonary angiography depends on renal function, previous contrast reactions, pregnancy, chest radiograph findings and local availability. A nondiagnostic result requires a subsequent decision; it must not be arbitrarily interpreted as positive or negative. Perfusion assessment retains a particularly important role in investigating chronic thromboembolic disease.

Venous ultrasonography may demonstrate deep vein thrombosis and, in appropriate settings of suspected pulmonary embolism, provide confirmation of the thromboembolic process sufficient to initiate treatment. However, a negative venous ultrasound examination of the limbs does not exclude pulmonary involvement. Echocardiography mainly assesses hemodynamic consequences: right ventricular dilation, reduced systolic function, septal abnormalities and estimated pressures. In stable patients, it is not a universal exclusion test; in shock, it may become crucial for rapidly guiding diagnosis and reperfusion when transfer for CT is unsafe.
Electrocardiography, chest radiography and arterial blood gas analysis complete the assessment and help identify other emergencies, but none of these investigations alone has sufficient accuracy to resolve the diagnostic suspicion.

Disease characterization after diagnostic confirmation

After confirmation, both early risk and the context that contributed to the event must be established. Blood pressure, peripheral perfusion, oxygen requirements, right ventricular function and cardiac biomarkers help determine the level of care. Troponin and natriuretic peptides have prognostic significance but may be abnormal in many other conditions: they do not independently prove the presence of pulmonary embolism and do not constitute an automatic indication for thrombolysis. Assessment must be dynamic because an initially compensated patient may develop progressively increasing oxygen requirements or signs of circulatory failure over the following hours.

Complete blood count, platelet count, renal and hepatic function and bleeding history provide the basis for safe treatment. Anticoagulant selection also depends on weight, gastrointestinal absorption, drug interactions, the ability to take medication regularly and previous reactions to heparin. Analysis of precipitating factors must distinguish conditions that have resolved from those that remain active, because treatment duration will depend primarily on the risk of new events after potential discontinuation. Extensive radiological involvement alone does not determine the need for permanent treatment.

Investigation for occult malignancy initially relies on the medical history, physical examination, basic investigations and age- and sex-appropriate screening programs. Symptoms, laboratory abnormalities or radiological findings guide any further assessment; an indiscriminate battery of whole-body investigations is not the standard response to every episode without an apparent cause. Similarly, thrombophilia testing must address a defined clinical question and have a potential impact on decisions. Some tests are affected by the acute phase or medications, and identification of an inherited variant does not automatically establish an indication for indefinite anticoagulation.

Reconstructing the timeline must also clarify whether the finding represents a first episode, a recurrence or a recent event superimposed on already organized disease. When available, previous imaging and data on exercise capacity help identify pre-existing abnormalities. An incidental finding requires dedicated clinical assessment because it may be accompanied by mild symptoms that were not initially reported; conversely, a residual finding does not necessarily represent a new episode. Radiological signs of chronic organization or right ventricular overload that is difficult to explain solely by the recent event guide subsequent evaluation. This distinction separates urgent decisions from investigation of sequelae and allows functional assessments to be scheduled at an appropriate time, while preserving a baseline against which recovery can be judged. The clinical record should therefore document the event location, initial cardiac findings and previous level of independence.

Treatment, recurrence prevention and prognosis

Anticoagulation is the foundation of treatment for most thrombotic pulmonary emboli. It reduces thrombus propagation and the formation of new embolic material, while removal of the existing clot depends largely on endogenous fibrinolysis and repair processes. This distinction explains why improvement should not be judged solely by the immediate disappearance of imaging abnormalities. In eligible patients, direct oral anticoagulants are generally preferred over vitamin K antagonists; when a parenteral phase is required, low-molecular-weight heparins are a standard option, with exceptions related to renal function, procedures and particular clinical conditions.

The choice is not identical in every setting. During pregnancy, low-molecular-weight heparins have a central role; direct oral anticoagulants are not recommended. In active malignancy, recurrence risk, mucosal bleeding, thrombocytopenia and interactions with cancer therapies must be considered together. In antiphospholipid antibody syndrome, particularly in high-risk profiles, vitamin K antagonists retain specific importance. Advanced renal impairment may limit several options and requires individualized drug and dose selection, without automatically applying to thromboembolism the dose-reduction regimens used for other indications.

Reperfusion by contrast, aims to reduce vascular obstruction rapidly. Systemic thrombolysis, catheter-based treatments and surgical embolectomy have a role in cases with circulatory failure or selected clinical deterioration, after assessment of bleeding risk, contraindications and available resources. The fact that a thrombus is visible or large does not, in itself, make an invasive procedure beneficial. In normotensive patients with right ventricular compromise, monitoring helps distinguish those who improve with anticoagulation from those requiring rescue intervention.
Multidisciplinary pulmonary embolism teams may facilitate this choice when cardiology, pulmonology, critical care, surgical and interventional expertise is needed within a short time.

Respiratory and circulatory support is adapted to right ventricular physiology. Oxygen corrects hypoxemia but does not remove the obstruction; excessive fluid loading may worsen ventricular dilation and left ventricular filling. Vasopressors, ventilation and mechanical circulatory support are reserved for appropriate cases and require particular attention to their effects on venous return and pulmonary vascular resistance. Inferior vena cava filters do not usually replace anticoagulation and are not routinely added when anticoagulation is feasible. If a retrievable filter is implanted because of a temporary contraindication, management must include reassessment of its necessity and planning for removal.

Primary treatment generally lasts at least three months; initial treatment phases are often described as lasting three to six months, followed by extended prevention when appropriate. A fully resolved major transient cause may allow discontinuation after the required course, whereas the absence of a major reversible factor, persistent risk or recurrence more often supports continuation. The decision must be reconsidered over time because age, renal function, comorbidities and concomitant therapies may alter the balance between thrombosis and bleeding. Reduced doses are available for some patients during the extended phase, depending on the indication and medication, and must not be confused with the therapeutic dosage required at presentation.

Early prognosis is primarily associated with hemodynamic stability and cardiopulmonary reserve; long-term prognosis also depends on recurrence, malignancy, bleeding and functional recovery. Discharge must include a clear plan covering the medication and dose, any changes in the treatment regimen, follow-up appointments, management of interactions and warning signs requiring urgent reassessment. New or rapidly worsening dyspnea, syncope, severe chest pain and significant bleeding must not automatically be attributed to recovery. Resumption of activity should be graduated according to individual circumstances, avoiding both premature exertion in patients with significant compromise and unjustified immobility when stabilization permits movement.

Complications and long-term consequences

The most severe acute complications arise from right ventricular pump failure: obstructive shock, multiorgan failure and cardiac arrest. Pulmonary infarction may cause pain, hemoptysis and pleural effusion; its presence must be distinguished from infection, malignancy or other causes of peripheral opacities. In a minority of cases, a thrombus crosses a right-to-left communication and reaches the systemic circulation. Paradoxical embolism may therefore associate a venous event with cerebral or other organ ischemia, but the mere presence of a patent foramen ovale does not establish that this mechanism has occurred.

Recurrence may occur after treatment discontinuation or, more rarely, during treatment. Before considering an anticoagulant ineffective, a new event must be documented and medication use, dosage, interactions, absorption and persistent procoagulant conditions must be assessed. Previous imaging is often crucial for distinguishing a new defect from a residual finding. Treatment itself may also cause complications: major bleeding, anemia, intracranial hemorrhage and drug-specific reactions must be recognized promptly, balancing bleeding control against the risk of leaving recent thromboembolic disease unprotected.

Post-pulmonary embolism syndrome describes a range of persistent limitations following the initial phase, including dyspnea, reduced exercise tolerance and impaired quality of life. Not every symptom is due to residual obstruction: deconditioning, cardiac disease, pulmonary disease, anemia and psychological consequences may contribute. Follow-up must therefore assess the patient’s actual recovery rather than simply checking whether medication is being taken regularly. Incomplete improvement requires targeted evaluation, including echocardiography, perfusion imaging, functional tests or cardiopulmonary exercise testing according to the clinical question.

In chronic thromboembolic pulmonary disease, organized material may form webs, stenoses and persistent occlusions. When this is associated with a pathological increase in pulmonary vascular pressures and resistance, chronic thromboembolic pulmonary hypertension is present. Suspicion arises particularly from persistent or recurrent dyspnea and exercise limitation after an adequate period of treatment; diagnosis requires specialist evaluation integrating symptoms, imaging and hemodynamic findings. An isolated residual radiological abnormality in an asymptomatic person is not equivalent to this diagnosis.

Recognition of these sequelae is clinically important because specific treatments are available, including pulmonary endarterectomy, balloon pulmonary angioplasty and targeted pharmacological therapy in indicated cases. Treatment selection requires an experienced center and multidisciplinary assessment of lesion distribution, operability and the microvascular component. In routine follow-up, however, CT pulmonary angiography need not be repeated systematically in every person who recovers well. It is more informative to combine scheduled clinical reassessment with monitoring of symptoms and functional capacity, maintaining this attention at least throughout the first year and longer when clinically indicated.

Bibliography
  1. Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2020;41(4):543–603.
  2. Creager MA et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2026;87(13):1626–1710.
  3. Huisman MV et al. Pulmonary embolism. Nature Reviews Disease Primers. 2018;4:18028.
  4. Heit JA. Epidemiology of venous thromboembolism. Nature Reviews Cardiology. 2015;12(8):464–474.
  5. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Reviews. 2009;23(5):225–229.
  6. Lim W et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Advances. 2018;2(22):3226–3256.
  7. Righini M et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–1124.
  8. van der Hulle T et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. The Lancet. 2017;390(10091):289–297.
  9. Rivera-Lebron B et al. Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clinical and Applied Thrombosis/Hemostasis. 2019;25:1076029619853037.
  10. Roy PM et al. Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal. 2021;42(33):3146–3157.
  11. Ortel TL et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances. 2020;4(19):4693–4738.
  12. Stevens SM et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545–e608.
  13. Bates SM et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances. 2018;2(22):3317–3359.
  14. Farge D et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet Oncology. 2022;23(7):e334–e347.
  15. Middeldorp S et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances. 2023;7(22):7101–7138.
  16. Carrier M et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. The New England Journal of Medicine. 2015;373(8):697–704.
  17. Meyer G et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. The New England Journal of Medicine. 2014;370(15):1402–1411.
  18. Khan F et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.
  19. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–3731.
  20. Klok FA et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal. 2022;43(3):183–189.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.